Arrowhead Pharmaceuticals, Inc. (LON:0HI3)
20.03
-0.79 (-3.80%)
At close: Feb 21, 2025
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $2.50M USD in the quarter ending December 31, 2024, a decrease of -29.60%. This brings the company's revenue in the last twelve months to $2.50M, down -98.62% year-over-year. In the fiscal year ending September 30, 2024, Arrowhead Pharmaceuticals had annual revenue of $3.55M, down -98.52%.
Revenue (ttm)
$2.50M
Revenue Growth
-98.62%
P/S Ratio
n/a
Revenue / Employee
$4.11K
Employees
609
Market Cap
1.99B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Arrowhead Pharmaceuticals News
- 4 days ago - Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions - Seeking Alpha
- 5 days ago - 20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset' - Market Watch
- 9 days ago - Avoro Capital Advisors LLC Increases Stake in Arrowhead Pharmaceuticals Inc - GuruFocus
- 12 days ago - Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... - GuruFocus
- 12 days ago - Arrowhead sees potential $2-3B annual sales for plozasiran in SHTG market by 2026 - Seeking Alpha
- 12 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Arrowhead Pharmaceuticals Inc (ARWR) Reports Q1 2025 Financial Results and Strategic Developments - GuruFocus
- 12 days ago - Arrowhead Pharmaceuticals Reports Q1 Loss of $1.39 EPS, Revenue at $2.5 Million, Missing Estimates - GuruFocus